July 2017

Important New Products

• Ibrance (palbociclib) is a small molecule inhibitor of cyclin dependent kinases (CDK) 4 and 6. ...(more)
• Naglazyme (galsulfase (rch)) is a normal variant form of the polymorphic human enzyme, ...(more)

New Indications

• Halaven (eribulin mesilate) is now indicated for the treatment of unresectable liposarcoma in ...(more)
• Keytruda (pembrolizumab (rch)) is now indicated for the first-line treatment of metastatic ...(more)

New Contraindications

• Codeine (Panamax Co, Prodeinextra (paracetamol/codeine phosphate hemihydrate) ...(more)
• Phenobarbitone Injection (Aspen Pharma) (phenobarbital (phenobarbitone)) is now ...(more)
• Pregnyl (human chorionic gonadotrophin) is now contraindicated with abnormal ...(more)
• Serenace (haloperidol), in common with other neuroleptics, has the potential to cause rare ...(more)
• Varilrix and Varilrix HSA-Free (varicella vaccine, live attenuated) are contraindicated with ...(more)
• Viekira Pak Combination Therapy Pack (paritaprevir/ritonavir/ombitasvir and dasabuvir) ...(more)

Active Ingredient Naming Changes

In this release, MIMS Australia will be including the following INNs (International Non-proprietary Names) as well as Australian Approved Names (AANs) as part of our push to support the Therapeutic Goods Administration (TGA) active ingredient name changes project.  

MIMS will begin referring to these ingredients by their new names, however, users may continue to search by the old AANs if preferred. ...(more)